Idorsia Ltd. (IDRSF)
4.70
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Idorsia Enterprise Value : 2.788B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 2.788B |
| November 12, 2026 | 2.788B |
| November 11, 2026 | 2.788B |
| November 10, 2026 | 2.861B |
| November 09, 2026 | 2.866B |
| November 06, 2026 | 2.855B |
| November 05, 2026 | 2.855B |
| November 04, 2026 | 2.855B |
| November 03, 2026 | 2.855B |
| November 02, 2026 | 2.855B |
| October 30, 2026 | 2.855B |
| October 29, 2026 | 2.855B |
| October 28, 2026 | 2.971B |
| October 27, 2026 | 2.971B |
| October 26, 2026 | 2.971B |
| October 23, 2026 | 2.971B |
| October 22, 2026 | 2.971B |
| October 21, 2026 | 2.971B |
| October 20, 2026 | 2.971B |
| October 19, 2026 | 2.971B |
| October 16, 2026 | 2.971B |
| October 15, 2026 | 2.971B |
| October 14, 2026 | 2.971B |
| October 13, 2026 | 2.971B |
| October 12, 2026 | 2.971B |
| Date | Value |
|---|---|
| October 09, 2026 | 2.971B |
| October 08, 2026 | 2.971B |
| October 07, 2026 | 2.971B |
| October 06, 2026 | 2.971B |
| October 05, 2026 | 2.971B |
| October 02, 2026 | 2.971B |
| October 01, 2026 | 2.977B |
| September 30, 2026 | 2.920B |
| September 29, 2026 | 2.920B |
| September 28, 2026 | 2.920B |
| September 25, 2026 | 2.949B |
| September 24, 2026 | 2.949B |
| September 23, 2026 | 3.028B |
| September 22, 2026 | 3.167B |
| September 21, 2026 | 3.167B |
| September 18, 2026 | 3.167B |
| September 17, 2026 | 3.167B |
| September 16, 2026 | 3.173B |
| September 15, 2026 | 3.173B |
| September 14, 2026 | 3.173B |
| September 11, 2026 | 3.173B |
| September 10, 2026 | 3.173B |
| September 09, 2026 | 3.204B |
| September 08, 2026 | 3.204B |
| September 04, 2026 | 3.196B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 40.06B |
| AC Immune SA | 110.19M |
| CRISPR Therapeutics AG | 2.598B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -65.28M |
| Revenue (Quarterly) | 76.24M |
| Total Expenses (Quarterly) | 141.51M |
| EPS Diluted (Quarterly) | -0.2452 |
| Gross Profit Margin (Quarterly) | 71.69% |
| Profit Margin (Quarterly) | -85.62% |
| Earnings Yield | -29.73% |
| Normalized Earnings Yield | -25.96 |